| Original language | English |
|---|---|
| Pages (from-to) | 555-557 |
| Number of pages | 3 |
| Journal | JACC: CardioOncology |
| Volume | 4 |
| Issue number | 4 |
| DOIs | |
| State | Published - Nov 2022 |
Bibliographical note
Funding Information:Mr Stabellini is supported through funding from the Sociedade Beneficente Israelita Brasileira Albert Einstein on the program “Marcos Lottenberg & Marcos Wolosker International Fellowship for Physicians Scientist – Case Western.” Dr Agarwal has served as a consultant for Astellas, AstraZeneca, Aveo, Bayer, Bristol Myers Squibb, Calithera, Clovis, Eisai, Eli Lilly, EMD Serono, Exelixis, Foundation Medicine, Genentech, Gilead, Janssen, Merck, MEI Pharma, Nektar, Novartis, Pfizer, Pharmacyclics, and Seattle Genetics; and has received research funding to the institution from Astellas, AstraZeneca, Bavarian Nordic, Bayer, Bristol Myers Squibb, Calithera, Celldex, Clovis, Eisai, Eli Lilly, EMD Serono, Exelixis, Genentech, Gilead, GlaxoSmithKline, Immunomedics, Janssen, Medivation, Merck, Nektar, New Link Genetics, Novartis, Pfizer, Prometheus, Rexahn, Roche, Sanofi, Seattle Genetics, Takeda, and Tracon. Dr Waite is a full-time, paid contractor of the NCI/NIH. Dr Barnholtz-Sloan is a full-time, paid employee of the NCI/NIH. Dr Guha is supported by American Heart Association-Strategically Focused Research Network Grants in Disparities in Cardio-Oncology (#847740, #863620). All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
ASJC Scopus subject areas
- Oncology
- Cardiology and Cardiovascular Medicine
